Latest California Healthline Stories
As Big Pharma Loses Interest in New Antibiotics, Infections Are Only Growing Stronger
Existing drugs still treat most infections. But that has discouraged investment in new drugs that will be needed when — not if —the old ones fail.
KHN’s ‘What the Health?’: Life After ‘Roe’ Is … Confusing
A rapidly changing landscape for abortion has left patients, providers, employers, and lawmakers alike wondering what is and is not legal and what to do next. Meanwhile, Democrats in Congress have resumed negotiations on legislation to lower drug prices and, potentially, continue expanded insurance subsidies for the Affordable Care Act. Alice Miranda Ollstein of Politico, Tami Luhby of CNN, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Patients With Epilepsy Navigate Murky Unregulated CBD Industry
The FDA has approved a cannabis-derived drug, Epidiolex, to treat some forms of epilepsy. Now people who have other forms of the condition are using over-the-counter CBD products in hopes of taming their seizures. But doctors and patients worry about the unregulated world of CBD, in which product ingredients can be a mystery.
How Pfizer Won the Pandemic, Reaping Outsize Profit and Influence
The drugmaker has the best-selling vaccine to prevent covid and the most effective drug to treat it. Its success has overshadowed the government’s covid-fighting strategy.
Cómo Pfizer le ganó a la pandemia, alcanzando influencia y ganancias descomunales
Su éxito en el desarrollo de medicamentos contra covid le ha dado a la farmacéutica un peso inusual en la determinación de la política de salud de Estados Unidos. Algo que preocupa a expertos.
KHN’s ‘What the Health?’: A World Without ‘Roe’
The Supreme Court’s decision overturning Roe v. Wade has created far more questions than it has answered about the continued legality and availability of abortion, as both abortion rights supporters and anti-abortion activists scramble to put their marks on policy. Meanwhile, Congress completes work on its gun bill and the FDA takes up the problem of the next covid-19 booster. Margot Sanger-Katz of The New York Times, Sarah Karlin-Smith of the Pink Sheet, and Victoria Knight of KHN join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Angela Hart, who reported and wrote the latest KHN-NPR “Bill of the Month” episode about two identical eye surgeries with very different price tags.
KHN’s ‘What the Health?’: The FDA Goes After Nicotine
The FDA is using its power to regulate tobacco products — ordering the vaping device Juul off the market and announcing its intention to lower the amount of nicotine in cigarettes and other products. Meanwhile, the Supreme Court rules on Medicare and kidney dialysis, and Congress makes progress on legislation surrounding guns and mental health. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Noam N. Levey about the new KHN-NPR project on the growing impact of medical debt.
New Weight Loss Treatment Is Marked by Heavy Marketing and Modest Results
Approved as a device, not a drug, Plenity contains a plant-based gel that swells to fill 25% of a person’s stomach, to help people eat less. Results vary widely but are modest on average.
Nuevo tratamiento para adelgazar: mucho marketing y resultados discretos
Plenity está aprobado por la FDA como un dispositivo que contiene granos de un hidrogel absorbente de origen vegetal. Cada grano se “infla” hasta 100 veces su tamaño, llenando una cuarta parte del estómago de una persona.
A Proposal to Import Drugs from Other Countries Creates an Unusual Alliance in the Senate
As a Senate committee considered legislation to reauthorize the FDA’s user fee program, Sens. Bernie Sanders and Rand Paul agreed on a proposed amendment related to importing drugs from Canada, the U.K., and other nations.